
Adona Medical
Advanced approaches for heart failure.
USD | 2022 |
---|---|
Revenues | 0000 |
EBITDA | 0000 |
Profit | 0000 |
EV | 0000 |
EV / revenue | 00.0x |
EV / EBITDA | 00.0x |
R&D budget | 0000 |
Source: Dealroom estimates
Related Content
Adona Medical, based in Los Gatos, CA, is a preclinical stage medical technology company and part of the Shifamed portfolio. The company focuses on developing advanced solutions for interatrial shunting and remote patient monitoring, specifically targeting patients with advanced heart failure. Interatrial shunting is a procedure that involves creating a small passage between the heart's atria to help manage pressure and blood flow, which can be crucial for heart failure patients. Remote patient monitoring involves using technology to keep track of patients' health data from a distance, allowing for better management and timely interventions.
Adona Medical's primary product, the Adona Medical System, is currently for investigational use only and is not available for sale in the U.S. or internationally. This system includes a novel interatrial shunt with integrated bi-atrial pressure monitoring. This means it can measure pressures in both atria (upper chambers of the heart) and adjust the shunt size to better manage the patient's condition over time. By reducing left atrial pressure (LAP) and unloading a small volume of blood into the right atrium (RA), the system aims to provide more individualized and effective management of heart failure.
The company operates in the medical technology market, specifically within the niche of heart failure management. Its clients are primarily healthcare providers and medical institutions that treat patients with advanced heart failure. Adona Medical's business model revolves around developing innovative medical devices that can eventually be commercialized and sold to these healthcare providers once they receive the necessary regulatory approvals.
Revenue generation for Adona Medical will likely come from the sale of its medical devices and potentially from partnerships or licensing agreements with larger medical technology companies. As the company is still in the preclinical stage, it is focused on research and development, clinical trials, and obtaining regulatory approvals.
Keywords: interatrial shunting, remote patient monitoring, heart failure, medical technology, preclinical stage, Shifamed portfolio, bi-atrial pressure monitoring, investigational use, healthcare providers, innovative medical devices.